Amneal announces additional interim Phase 4 ELEVATE-PD study results

Amneal Pharmaceuticals (AMRX) announced new positive interim results from its ongoing Phase 4 ELEVATE-PD study, presented at the 2026 American Academy of Neurology, AAN. The first 111 patients evaluated after six weeks of treatment demonstrated substantial clinical benefit after switching to CREXONT extended-release capsules, regardless of whether patients switched from immediate-release carbidopa/levodopa, IR CD/LD plus a COMT inhibitor, or RYTARY extended-release capsules. These interim findings build on the established efficacy and safety profile of CREXONT demonstrated in the Phase 3 RISE-PD trial and reflected in the FDA-approved prescribing information. After patients switched from prior therapies, treatment with CREXONT delivered meaningful increases in “Good On” time, reductions in “Off” time, and improved motor symptom control. Patients switching from RYTARY achieved consistent gains in continuous “Good On” intervals – the length of uninterrupted time patients spend feeling their best.